Yesterday, July 27, 2016, 50 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $202.10 to $4,537,018.08.

Highlighted Stocks Traded by Insiders:

Tupperware Brands (TUP) - FREE Research Report

Gupta Asha, who is Group President at Tupperware Brands, sold 917 shares at $62.70 on July 27, 2016. Following this transaction, the Group President owned 15,000 shares meaning that the stake was reduced by 5.76% with the 917-share transaction.

The shares most recently traded at $62.49, down $0.21, or 0.34% since the insider transaction. Historical insider transactions for Tupperware Brands go as follows:

  • 4-Week # shares bought: 2,500
  • 4-Week # shares sold: 162,000
  • 12-Week # shares bought: 2,500
  • 12-Week # shares sold: 166,555
  • 24-Week # shares bought: 2,500
  • 24-Week # shares sold: 171,530

The average volume for Tupperware Brands has been 631,700 shares per day over the past 30 days. Tupperware Brands has a market cap of $3.2 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 11.84% year-to-date as of the close of trading on Wednesday.

Tupperware Brands Corporation operates as a direct-to-consumer marketer of various products across a range of brands and categories worldwide. The stock currently has a dividend yield of 4.34%. The company has a P/E ratio of 16.6. Currently, there are no analysts who rate Tupperware Brands a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TUP - FREE

TheStreet Quant Ratings

rates Tupperware Brands as a

buy

. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins and notable return on equity. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Tupperware Brands Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Quest Diagnostics (DGX) - FREE Research Report

Ziegler John B, who is Director at Quest Diagnostics, sold 1,000 shares at $84.36 on July 27, 2016. Following this transaction, the Director owned 18,557 shares meaning that the stake was reduced by 5.11% with the 1,000-share transaction.

The shares most recently traded at $84.49, up $0.13, or 0.16% since the insider transaction. Historical insider transactions for Quest Diagnostics go as follows:

  • 4-Week # shares bought: 4,000
  • 4-Week # shares sold: 5,883
  • 12-Week # shares bought: 4,000
  • 12-Week # shares sold: 5,883
  • 24-Week # shares bought: 4,000
  • 24-Week # shares sold: 9,308

The average volume for Quest Diagnostics has been 1.2 million shares per day over the past 30 days. Quest Diagnostics has a market cap of $11.8 billion and is part of the health care sector and health services industry. Shares are up 18.51% year-to-date as of the close of trading on Wednesday.

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The stock currently has a dividend yield of 1.88%. The company has a P/E ratio of 14.8. Currently, there is 1 analyst who rates Quest Diagnostics a buy, 2 analysts rate it a sell, and 13 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DGX - FREE

TheStreet Quant Ratings

rates Quest Diagnostics as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, notable return on equity and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Quest Diagnostics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Exponent (EXPO) - FREE Research Report

Boehm Paul, who is Group Vice President at Exponent, sold 5,000 shares at $51.42 on July 27, 2016. Following this transaction, the Group Vice President owned 29,045 shares meaning that the stake was reduced by 14.69% with the 5,000-share transaction.

The shares most recently traded at $51.65, up $0.23, or 0.44% since the insider transaction. Historical insider transactions for Exponent go as follows:

  • 4-Week # shares sold: 16,578
  • 12-Week # shares sold: 66,033
  • 24-Week # shares sold: 76,233

The average volume for Exponent has been 125,400 shares per day over the past 30 days. Exponent has a market cap of $1.3 billion and is part of the services sector and diversified services industry. Shares are up 3.66% year-to-date as of the close of trading on Wednesday.

Exponent, Inc., together with its subsidiaries, operates as a science and engineering consulting company worldwide. It operates in two segments, Engineering and Other Scientific; and Environmental and Health. The stock currently has a dividend yield of 1.39%. The company has a P/E ratio of 29.6. Currently, there are no analysts who rate Exponent a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EXPO - FREE

TheStreet Quant Ratings

rates Exponent as a

buy

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Exponent Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.